Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan

被引：22

作者：

O'Reilly, S ^{[1
]}

Armstrong, DK ^{[1
]}

Grochow, LB ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA

来源：

关键词：

D O I：

10.1006/gyno.1997.4896

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：329 / 330

页数：2

共 4 条

[1] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
COCKCROFT, DW
GAULT, MH
[J]. NEPHRON, 1976, 16 (01) : 31 - 41
[2] Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
Huinink, WTB
Gore, M
Carmichael, J
Gordon, A
Malfetano, J
Hudson, I
Broom, C
Scarabelli, C
Davidson, N
Spanczynski, M
Bolis, G
Malmstrom, H
Coleman, R
Fields, SC
Heron, JF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2183 - 2193
[3] JELIFFE RW, 1973, ANN INTERN MED, V79, P604
[4] Phase I and pharmacologic study of topotecan in patients with impaired renal function
OReilly, S
Rowinsky, EK
Slichenmyer, W
Donehower, RC
Forastiere, AA
Ettinger, DS
Chen, TL
Sartorius, S
Grochow, LB
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (12) : 3062 - 3073